Figure 1
Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable
09. Januar 2023 07:00 ET | Entrada Therapeutics, Inc.
BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Logo.png
Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy
19. Dezember 2022 16:30 ET | Entrada Therapeutics, Inc.
BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Logo.png
Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
22. November 2022 07:00 ET | Entrada Therapeutics, Inc.
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular...
Entrada Logo.png
Entrada Therapeutics Reports Third Quarter 2022 Financial Results
07. November 2022 07:00 ET | Entrada Therapeutics, Inc.
On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 for the potential treatment of patients with Duchenne muscular dystrophy who are exon...
Entrada Logo.png
Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
30. August 2022 07:00 ET | Entrada Therapeutics, Inc.
BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Logo.png
Entrada Therapeutics Reports Second Quarter 2022 Financial Results
11. August 2022 07:00 ET | Entrada Therapeutics, Inc.
On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 targeting Duchenne muscular dystrophy in Q4 2022 Cash runway into 2H 2024 with $244...
Entrada Logo.png
Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1
04. August 2022 07:00 ET | Entrada Therapeutics, Inc.
The natural history study will generate data to further the ongoing efforts of the myotonic dystrophy research community to understand disease progression and identify potential clinical outcome...
Entrada Logo.png
Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer
19. Juli 2022 07:00 ET | Entrada Therapeutics, Inc.
BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Logo.png
Entrada Therapeutics to Present at William Blair Biotech Focus Conference
06. Juli 2022 07:00 ET | Entrada Therapeutics, Inc.
BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Logo.png
Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference
01. Juni 2022 07:00 ET | Entrada Therapeutics, Inc.
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...